Dados B3 › FASA3 × JBSS3
FASA3 × JBSS3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | FASA3 | JBSS3 | year |
|---|---|---|---|
| ROE | 0.0%! | 24.8% | 2025 |
| ROIC | -70.7%! | 14.4% | 2025 |
| ROA | -57.3%! | 5.0% | 2025 |
| Gross margin | -3.6% | 13.1% | 2025 |
| EBIT margin | -29.8% | 4.9% | 2025 |
| Net margin | -30.4% | 2.6% | 2025 |
| Net debt/EBITDA | -2.46x | 2.28x | 2022 |
| Current ratio | 1.39x | 1.60x | 2025 |
| Revenue growth (1y) | -100.0%! | 14.6% | 2024 |
| Revenue growth (5y CAGR) | 20.1% | 12.2% | 2025 |
| Piotroski F-Score | 4/9! | 7/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | FASA3 | JBSS3 | year |
|---|---|---|---|
| P/E | — | 9.40x | 2025 × 2024 |
| P/B | 0.25x | 2.02x | 2025 × 2024 |
| EV/EBITDA | — | 4.90x | 2025 × 2024 |
| FCF yield | -261.4% | 17.1% | 2025 × 2024 |
Numbers on this page are live. Data version 2026-09-27-reapresentacao-agreg · page generated 2026-09-27 07:14 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.
Numbers on this page are live. Data version 2026-09-27-reapresentacao-agreg · page generated 2026-09-27 07:14 UTC. If this does not match /saude, you are reading a cached copy.